YOLFTbeta
Island Pharmaceuticals Ltd

Island Pharmaceuticals Ltd

ILA · AU · Healthcare / Biotechnology

0.295AUD-0.02 (-6.35%)

Price History

Full chart

Market Stats

Previous Close0.315
Open0.31
Day Range0.295 – 0.31
52-Week Range0.31 – 0.63
Volume240.28K
Market Cap114.00M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.04
Dividend Yield0.00%
Beta0.12
50-Day Avg0.4303
200-Day Avg0.4046

About

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company's lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. David Charles Foster J.D., M.A.I.C.D., Ph.D.
  • Employees0
  • Headquarters117 Camberwell Road, Hawthorn East, VIC, Australia, 3123, Australia
  • Websitehttps://www.islandpharmaceuticals.com

Leadership

  • Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D.MD, CEO & Executive Director
  • Mr. Cameron Peter Jones C.A.CFO & Company Secretary

Financials

Income Statement

Currency: AUD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-00011.06K1.25M118.91K282.66K
Growth (%)-----+11211.12%-90.50%+137.71%
Cost of Revenue----1.14M2.26M1.40M105.29K
Gross Profit----11.06K-1.01M-1.29M-105.29K
Gross Margin----100.00%-80.78%-1081.42%-37.25%
Operating Expense----2.92M4.13M4.07M10.51M
Operating Income-430.00K-658-2.14M-2.81M-2.91M-5.14M-5.36M-10.62M
Operating Margin-----26282.24%-410.39%-4507.49%-3756.31%
EBITDA---2.14M-2.81M-2.82M-2.82M-4.07M-10.51M
EBITDA Margin-----25498.83%-225.17%-3426.06%-3719.06%
Net Income-430.00K-658-2.13M-2.61M-2.83M-2.86M-3.92M-9.84M
Net Income Margin-----25580.20%-228.86%-3296.73%-3482.66%
R&D126.00K-2.59K1.03M1.14M2.27M1.40M2.86M
R&D as % of Total Revenue----10308.57%181.58%1181.42%1013.18%
Interest Expense-0009.00K46.20K27.31K-
Interest Expense % of Total Revenue----81.34%3.69%22.96%-

Balance Sheet

Currency: AUD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets176.64M4.90M2.05M2.56M7.49M14.00M
Total Liabilities674236.83K580.73K263.85K1.05M336.43K538.52K
Total Equity-6576.40M4.32M1.79M1.52M7.16M13.46M
Cash16.46M4.79M2.00M1.66M7.25M12.87M
Total Debt----421.97K--
Net Debt-1-6.46M-4.79M-2.00M-1.24M-7.25M-12.87M

Cash Flow

Currency: AUD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-376.00K-16-938.24K-1.88M-2.71M-3.16M-2.77M-4.83M
Investing Cash Flow-77.37K77.37K0000-841.70K
Financing Cash Flow1.59M7.30M7.30M-180.36K-171.36K2.79M8.36M11.11M
Capital Expenditure0040025841.70K
Free Cash Flow-376.00K-16-938.24K-1.88M-2.71M-3.16M-2.77M-4.83M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateApr 9, 2021Aug 26, 2021Feb 24, 2022Aug 25, 2022Feb 23, 2023Feb 25, 2024May 29, 2024Aug 29, 2024Nov 27, 2024Feb 27, 2025May 28, 2025Aug 28, 2025Dec 3, 2025Feb 25, 2026
EPS Estimate0.000.000.000.000.00-0.000.000.000.000.000.000.000.000.00
EPS Actual-0.03-0.03-0.01-0.02-0.02-0.010.000.000.00-0.010.00-0.010.000.00
Surprise------13100.00%--------
Timing--------------

Key Statistics & Ratios

Market Cap114.00M
Enterprise Value107.05M
Trailing P/E0.00
Forward P/E0.00
Price / Sales403.06
Price / Book8.91
EPS-0.04
Book Value0.045
Revenue (TTM)282.66K
Gross Profit (TTM)-2.58M
EBITDA-10.23M
Profit Margin0.00%
Operating Margin-2240.47%
Return on Equity-95.51%
Return on Assets-60.12%
Shares Outstanding296.10M
Shares Float171.78M
Beta0.12
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%